<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03603106</url>
  </required_header>
  <id_info>
    <org_study_id>GDX-44-003</org_study_id>
    <secondary_id>2013-004428-12</secondary_id>
    <nct_id>NCT03603106</nct_id>
  </id_info>
  <brief_title>Pharmacokinetics, Pharmacodynamics Profile and Tolerance of P03277 in Healthy Subjects and Patients With Brain Lesions</brief_title>
  <official_title>Assessment of Pharmacokinetics, Pharmacodynamics Profile and Tolerance of P03277 in Healthy Subjects and Patients With Brain Lesions</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Guerbet</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Guerbet</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary objective of this study was to evaluate the safety (clinical and biological) and
      pharmacokinetics (plasma and urine) profile of P03277 following single administration at
      ascending dose levels in healthy subjects.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This single-center, single ascending dose, phase I/IIa study was divided into 2 parts,
      involving both healthy subjects and patients with brain lesions:

        -  Study Part I included healthy subjects: double-blind, randomized, placebo control;

        -  Study Part II included patients with brain lesions: open-label.

      In Part I, the following 6 dosing groups were investigated:

        -  Group 1: 0.025 mmol/kg

        -  Group 2: 0.05 mmol/kg

        -  Group 3: 0.075 mmol/kg

        -  Group 4: 0.1 mmol/kg

        -  Group 5: 0.2 mmol/kg

        -  Group 6: 0.3 mmol/kg

      Healthy subjects were included and were then administered with P03277 or placebo and were to
      undergo MRI examination according to the randomization scheme.

      In Part II, the following 4 doses groups were investigated:

        -  Group 7: 0.05 mmol/kg

        -  Group 8: 0.075 mmol/kg

        -  Group 9: 0.1 mmol/kg

        -  Group 10: 0.2 mmol/kg

      Patients with brain lesions were included and were then administered with P03277 and
      underwent MRI examination.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">November 25, 2013</start_date>
  <completion_date type="Actual">April 17, 2015</completion_date>
  <primary_completion_date type="Actual">April 17, 2015</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <intervention_model_description>Part I: Sequential administration within each group of healthy subjects was established.
Part II: The administration to patients within the same day was sequential to ensure the well-being of the patients. At least a 1-hour interval between 2 administrations had to be respected.</intervention_model_description>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Pharmacokinetic (PK) Parameter Cmax</measure>
    <time_frame>From baseline (30 minutes before injection) to 24 hours post-injection</time_frame>
    <description>Cmax = maximum concentration measured. Blood samples were taken to assess the P03277 concentration.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>PK Parameter T1/2</measure>
    <time_frame>From baseline (30 minutes before injection) to 24 hours post-injection</time_frame>
    <description>T1/2 = terminal elimination half-life of the compound. Blood samples were taken to assess the P03277 concentration.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>PK Parameter Cl</measure>
    <time_frame>From baseline (30 minutes before injection) to 24 hours post-injection</time_frame>
    <description>Cl = total clearance. Blood samples were taken to assess the P03277 concentration.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>PK Parameter Vd</measure>
    <time_frame>From baseline (30 minutes before injection) to 24 hours post-injection</time_frame>
    <description>Vd = volume of distribution. Blood samples were taken to assess the P03277 concentration.</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">142</enrollment>
  <condition>Healthy Volunteers</condition>
  <condition>Brain Lesion</condition>
  <arm_group>
    <arm_group_label>Part I (Phase I)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>In each dose group (0.025, 0.05, 0.075, 0.1, 0.2 and 0.3 mmol/kg), 9 healthy subjects were to be included: 6 subjects received P03277 and 3 subjects received placebo in one single intravenous administration.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part II (Phase IIA)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>In each dose group (0.05, 0.075, 0.1 and 0.2 mmol/kg), all 3 patients received one single intravenous administration of P03277.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>P03277</intervention_name>
    <description>Part I: P03277 was administered intravenously with a flow rate ranging from 0.5 to 2 mL/s.
Part II: P03277 was administered intravenously with a flow rate of 2 mL/s.</description>
    <arm_group_label>Part I (Phase I)</arm_group_label>
    <arm_group_label>Part II (Phase IIA)</arm_group_label>
    <other_name>Gadopiclenol</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Part I: Placebo was administered intravenously with a flow rate ranging from 0.5 to 2 mL/s.
Part II: Placebo was administered intravenously with a flow rate of 2 mL/s.</description>
    <arm_group_label>Part I (Phase I)</arm_group_label>
    <other_name>NaCl 0.9%</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Part I: Subjects between 18 and 45 years old (inclusive), with a body mass index (BMI)
             of 18 to 30 kg/mÂ² (exclusive) and in a good health.

          -  Part II: Patients 18 years old and older and having at least one brain lesion with a
             disruption of the blood brain barrier (BBB) and/or with abnormal vascularity in the
             brain. This/these lesion(s) must have been detected by previous imaging evaluation
             (Computed Tomography or MRI).
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Wouter Haazen, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>SGS Clinical Pharmacology Unit</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Clinical Pharmacology unit, SGS Life Science Services</name>
      <address>
        <city>Antwerpen</city>
        <zip>2060</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Belgium</country>
  </location_countries>
  <verification_date>April 2019</verification_date>
  <study_first_submitted>July 16, 2018</study_first_submitted>
  <study_first_submitted_qc>July 26, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">July 27, 2018</study_first_posted>
  <results_first_submitted>November 20, 2018</results_first_submitted>
  <results_first_submitted_qc>April 29, 2019</results_first_submitted_qc>
  <results_first_posted type="Actual">July 12, 2019</results_first_posted>
  <last_update_submitted>April 29, 2019</last_update_submitted>
  <last_update_submitted_qc>April 29, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">July 12, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <pre_assignment_details>For part I, all patients who were not randomized were screening failures. For part II, all patients who were not allocated to a dose of P03277 were screening failures.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Part I (Phase I) P03277 0.025 mmol/kg</title>
          <description>6 subjects received P03277 in one single administration. P03277 was administered intravenously at 0.025 mmol/kg with a flow rate ranging from 0.5 to 2 mL/s.</description>
        </group>
        <group group_id="P2">
          <title>Part I (Phase I) P03277 0.05 mmol/kg</title>
          <description>6 subjects received P03277 in one single administration. P03277 was administered intravenously at 0.05 mmol/kg with a flow rate ranging from 0.5 to 2 mL/s.</description>
        </group>
        <group group_id="P3">
          <title>Part I (Phase I) P03277 0.075 mmol/kg</title>
          <description>6 subjects received P03277 in one single administration. P03277 was administered intravenously at 0.075 mmol/kg with a flow rate ranging from 0.5 to 2 mL/s.</description>
        </group>
        <group group_id="P4">
          <title>Part I (Phase I) P03277 0.1 mmol/kg</title>
          <description>6 subjects received P03277 in one single administration. P03277 was administered intravenously at 0.1 mmol/kg with a flow rate ranging from 0.5 to 2 mL/s.</description>
        </group>
        <group group_id="P5">
          <title>Part I (Phase I) P03277 0.2 mmol/kg</title>
          <description>6 subjects received P03277 in one single administration. P03277 was administered intravenously at 0.2 mmol/kg with a flow rate ranging from 0.5 to 2 mL/s.</description>
        </group>
        <group group_id="P6">
          <title>Part I (Phase I) P03277 0.3 mmol/kg</title>
          <description>6 subjects received P03277 in one single administration. P03277 was administered intravenously at 0.3 mmol/kg with a flow rate ranging from 0.5 to 2 mL/s.</description>
        </group>
        <group group_id="P7">
          <title>Part I (Phase I) Placebo</title>
          <description>3 healthy subjects per dose group received placebo in one single administration.
Placebo was administered intravenously with a flow rate ranging from 0.5 to 2 mL/s.</description>
        </group>
        <group group_id="P8">
          <title>Part II (Phase IIA) P03277 0.05 mmol/kg</title>
          <description>3 patients received one single administration of P03277. P03277 was administered intravenously at 0.05 mmol/kg with a flow rate of 2 mL/s.</description>
        </group>
        <group group_id="P9">
          <title>Part II (Phase IIA) P03277 0.075 mmol/kg</title>
          <description>3 patients received one single administration of P03277. P03277 was administered intravenously at 0.075 mmol/kg with a flow rate of 2 mL/s.</description>
        </group>
        <group group_id="P10">
          <title>Part II (Phase IIA) P03277 0.1 mmol/kg</title>
          <description>3 patients received one single administration of P03277. P03277 was administered intravenously at 0.1 mmol/kg with a flow rate of 2 mL/s.</description>
        </group>
        <group group_id="P11">
          <title>Part II (Phase IIA) P03277 0.2 mmol/kg</title>
          <description>3 patients received one single administration of P03277. P03277 was administered intravenously at 0.2 mmol/kg with a flow rate of 2 mL/s.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="6"/>
                <participants group_id="P3" count="6"/>
                <participants group_id="P4" count="6"/>
                <participants group_id="P5" count="6"/>
                <participants group_id="P6" count="6"/>
                <participants group_id="P7" count="18"/>
                <participants group_id="P8" count="3"/>
                <participants group_id="P9" count="3"/>
                <participants group_id="P10" count="3"/>
                <participants group_id="P11" count="3"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="6"/>
                <participants group_id="P3" count="6"/>
                <participants group_id="P4" count="6"/>
                <participants group_id="P5" count="6"/>
                <participants group_id="P6" count="6"/>
                <participants group_id="P7" count="18"/>
                <participants group_id="P8" count="3"/>
                <participants group_id="P9" count="3"/>
                <participants group_id="P10" count="3"/>
                <participants group_id="P11" count="3"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
                <participants group_id="P11" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>All patients who received one injection of product (placebo or P03277 for Part I, P03277 for Part II).</population>
      <group_list>
        <group group_id="B1">
          <title>Part I (Phase I) P03277 0.025 mmol/kg</title>
          <description>6 subjects received P03277 in one single administration.
P03277 was administered intravenously at 0.025 mmol/kg with a flow rate ranging from 0.5 to 2 mL/s.</description>
        </group>
        <group group_id="B2">
          <title>Part I (Phase I) P03277 0.05 mmol/kg</title>
          <description>6 subjects received P03277 in one single administration.
P03277 was administered intravenously at 0.05 mmol/kg with a flow rate ranging from 0.5 to 2 mL/s.</description>
        </group>
        <group group_id="B3">
          <title>Part I (Phase I) P03277 0.075 mmol/kg</title>
          <description>6 subjects received P03277 in one single administration.
P03277 was administered intravenously at 0.075 mmol/kg with a flow rate ranging from 0.5 to 2 mL/s.</description>
        </group>
        <group group_id="B4">
          <title>Part I (Phase I) P03277 0.1 mmol/kg</title>
          <description>6 subjects received P03277 in one single administration.
P03277 was administered intravenously at 0.1 mmol/kg with a flow rate ranging from 0.5 to 2 mL/s.</description>
        </group>
        <group group_id="B5">
          <title>Part I (Phase I) P03277 0.2 mmol/kg</title>
          <description>6 subjects received P03277 in one single administration.
P03277 was administered intravenously at 0.2 mmol/kg with a flow rate ranging from 0.5 to 2 mL/s.</description>
        </group>
        <group group_id="B6">
          <title>Part I (Phase I) P03277 0.3 mmol/kg</title>
          <description>6 subjects received P03277 in one single administration.
P03277 was administered intravenously at 0.3 mmol/kg with a flow rate ranging from 0.5 to 2 mL/s.</description>
        </group>
        <group group_id="B7">
          <title>Part I (Phase I) Placebo</title>
          <description>3 healthy subjects per dose group received placebo in one single administration.
Placebo was administered intravenously with a flow rate ranging from 0.5 to 2 mL/s.</description>
        </group>
        <group group_id="B8">
          <title>Part II (Phase IIA) P03277 0.05 mmol/kg</title>
          <description>3 patients received one single administration of P03277.
P03277 was administered intravenously at 0.05 mmol/kg with a flow rate of 2 mL/s.</description>
        </group>
        <group group_id="B9">
          <title>Part II (Phase IIA) P03277 0.075 mmol/kg</title>
          <description>3 patients received one single administration of P03277.
P03277 was administered intravenously at 0.075 mmol/kg with a flow rate of 2 mL/s.</description>
        </group>
        <group group_id="B10">
          <title>Part II (Phase IIA) P03277 0.1 mmol/kg</title>
          <description>3 patients received one single administration of P03277.
P03277 was administered intravenously at 0.1 mmol/kg with a flow rate of 2 mL/s.</description>
        </group>
        <group group_id="B11">
          <title>Part II (Phase IIA) P03277 0.2 mmol/kg</title>
          <description>3 patients received one single administration of P03277.
P03277 was administered intravenously at 0.2 mmol/kg with a flow rate of 2 mL/s.</description>
        </group>
        <group group_id="B12">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="6"/>
            <count group_id="B2" value="6"/>
            <count group_id="B3" value="6"/>
            <count group_id="B4" value="6"/>
            <count group_id="B5" value="6"/>
            <count group_id="B6" value="6"/>
            <count group_id="B7" value="18"/>
            <count group_id="B8" value="3"/>
            <count group_id="B9" value="3"/>
            <count group_id="B10" value="3"/>
            <count group_id="B11" value="3"/>
            <count group_id="B12" value="66"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="26.0" lower_limit="22" upper_limit="30"/>
                    <measurement group_id="B2" value="25.5" lower_limit="21" upper_limit="37"/>
                    <measurement group_id="B3" value="27.5" lower_limit="23" upper_limit="40"/>
                    <measurement group_id="B4" value="25.5" lower_limit="23" upper_limit="41"/>
                    <measurement group_id="B5" value="23.0" lower_limit="18" upper_limit="36"/>
                    <measurement group_id="B6" value="33.5" lower_limit="23" upper_limit="42"/>
                    <measurement group_id="B7" value="26.5" lower_limit="19" upper_limit="43"/>
                    <measurement group_id="B8" value="40.0" lower_limit="37" upper_limit="50"/>
                    <measurement group_id="B9" value="56.0" lower_limit="25" upper_limit="57"/>
                    <measurement group_id="B10" value="56.0" lower_limit="53" upper_limit="61"/>
                    <measurement group_id="B11" value="53.0" lower_limit="50" upper_limit="58"/>
                    <measurement group_id="B12" value="28.0" lower_limit="18" upper_limit="61"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="3"/>
                    <measurement group_id="B4" value="3"/>
                    <measurement group_id="B5" value="3"/>
                    <measurement group_id="B6" value="3"/>
                    <measurement group_id="B7" value="8"/>
                    <measurement group_id="B8" value="1"/>
                    <measurement group_id="B9" value="2"/>
                    <measurement group_id="B10" value="1"/>
                    <measurement group_id="B11" value="1"/>
                    <measurement group_id="B12" value="32"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="3"/>
                    <measurement group_id="B4" value="3"/>
                    <measurement group_id="B5" value="3"/>
                    <measurement group_id="B6" value="3"/>
                    <measurement group_id="B7" value="10"/>
                    <measurement group_id="B8" value="2"/>
                    <measurement group_id="B9" value="1"/>
                    <measurement group_id="B10" value="2"/>
                    <measurement group_id="B11" value="2"/>
                    <measurement group_id="B12" value="34"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Weight</title>
          <units>kg</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="81.65" lower_limit="52.2" upper_limit="87.4"/>
                    <measurement group_id="B2" value="71.60" lower_limit="54.0" upper_limit="83.6"/>
                    <measurement group_id="B3" value="65.00" lower_limit="56.4" upper_limit="93.0"/>
                    <measurement group_id="B4" value="72.50" lower_limit="62.0" upper_limit="99.2"/>
                    <measurement group_id="B5" value="69.30" lower_limit="68.2" upper_limit="87.6"/>
                    <measurement group_id="B6" value="72.50" lower_limit="61.6" upper_limit="88.6"/>
                    <measurement group_id="B7" value="67.90" lower_limit="56.8" upper_limit="89.4"/>
                    <measurement group_id="B8" value="87.20" lower_limit="85.8" upper_limit="89.0"/>
                    <measurement group_id="B9" value="80.40" lower_limit="71.2" upper_limit="87.4"/>
                    <measurement group_id="B10" value="87.20" lower_limit="82.4" upper_limit="102.8"/>
                    <measurement group_id="B11" value="85.80" lower_limit="79.4" upper_limit="101.6"/>
                    <measurement group_id="B12" value="72.85" lower_limit="52.2" upper_limit="102.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Pharmacokinetic (PK) Parameter Cmax</title>
        <description>Cmax = maximum concentration measured. Blood samples were taken to assess the P03277 concentration.</description>
        <time_frame>From baseline (30 minutes before injection) to 24 hours post-injection</time_frame>
        <population>In part I, one patient from the &quot;0.025 mmol/kg&quot; group was excluded from the pharmacokinetics analysis (incorrect volume of P03277 injected).
In part II, one patient from the &quot;0.1 mmol/kg&quot; group was excluded from the pharmacokinetics analysis (incorrect route of administration, high probability of extravasation).</population>
        <group_list>
          <group group_id="O1">
            <title>Part I (Phase I) P03277 0.025 mmol/kg</title>
            <description>6 subjects received P03277 in one single administration. P03277 was administered intravenously at 0.025 mmol/kg with a flow rate ranging from 0.5 to 2 mL/s.</description>
          </group>
          <group group_id="O2">
            <title>Part I (Phase I) P03277 0.05 mmol/kg</title>
            <description>6 subjects received P03277 in one single administration. P03277 was administered intravenously at 0.05 mmol/kg with a flow rate ranging from 0.5 to 2 mL/s.</description>
          </group>
          <group group_id="O3">
            <title>Part I (Phase I) P03277 0.075 mmol/kg</title>
            <description>6 subjects received P03277 in one single administration. P03277 was administered intravenously at 0.075 mmol/kg with a flow rate ranging from 0.5 to 2 mL/s.</description>
          </group>
          <group group_id="O4">
            <title>Part I (Phase I) P03277 0.1 mmol/kg</title>
            <description>6 subjects received P03277 in one single administration. P03277 was administered intravenously at 0.1 mmol/kg with a flow rate ranging from 0.5 to 2 mL/s.</description>
          </group>
          <group group_id="O5">
            <title>Part I (Phase I) P03277 0.2 mmol/kg</title>
            <description>6 subjects received P03277 in one single administration. P03277 was administered intravenously at 0.2 mmol/kg with a flow rate ranging from 0.5 to 2 mL/s.</description>
          </group>
          <group group_id="O6">
            <title>Part I (Phase I) P03277 0.3 mmol/kg</title>
            <description>6 subjects received P03277 in one single administration. P03277 was administered intravenously at 0.3 mmol/kg with a flow rate ranging from 0.5 to 2 mL/s.</description>
          </group>
          <group group_id="O7">
            <title>Part II (Phase IIA) 0.05 mmol/kg</title>
            <description>3 patients received one single administration of P03277. P03277 was administered intravenously at 0.05 mmol/kg with a flow rate of 2 mL/s.</description>
          </group>
          <group group_id="O8">
            <title>Part II (Phase IIA) 0.075 mmol/kg</title>
            <description>3 patients received one single administration of P03277. P03277 was administered intravenously at 0.075 mmol/kg with a flow rate of 2 mL/s.</description>
          </group>
          <group group_id="O9">
            <title>Part II (Phase IIA) 0.1 mmol/kg</title>
            <description>3 patients received one single administration of P03277. P03277 was administered intravenously at 0.1 mmol/kg with a flow rate of 2 mL/s.</description>
          </group>
          <group group_id="O10">
            <title>Part II (Phase IIA) 0.2 mmol/kg</title>
            <description>3 patients received one single administration of P03277. P03277 was administered intravenously at 0.2 mmol/kg with a flow rate of 2 mL/s.</description>
          </group>
        </group_list>
        <measure>
          <title>Pharmacokinetic (PK) Parameter Cmax</title>
          <description>Cmax = maximum concentration measured. Blood samples were taken to assess the P03277 concentration.</description>
          <population>In part I, one patient from the &quot;0.025 mmol/kg&quot; group was excluded from the pharmacokinetics analysis (incorrect volume of P03277 injected).
In part II, one patient from the &quot;0.1 mmol/kg&quot; group was excluded from the pharmacokinetics analysis (incorrect route of administration, high probability of extravasation).</population>
          <units>Âµg/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="5"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="6"/>
                <count group_id="O5" value="6"/>
                <count group_id="O6" value="6"/>
                <count group_id="O7" value="3"/>
                <count group_id="O8" value="3"/>
                <count group_id="O9" value="2"/>
                <count group_id="O10" value="3"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="248.7" spread="54.5"/>
                    <measurement group_id="O2" value="524.5" spread="69.9"/>
                    <measurement group_id="O3" value="698.7" spread="378.9"/>
                    <measurement group_id="O4" value="992.0" spread="233.1"/>
                    <measurement group_id="O5" value="2097.6" spread="572.3"/>
                    <measurement group_id="O6" value="3916.4" spread="1114.8"/>
                    <measurement group_id="O7" value="370.8" spread="117.6"/>
                    <measurement group_id="O8" value="618.2" spread="439.7"/>
                    <measurement group_id="O9" value="701.6" spread="48.5"/>
                    <measurement group_id="O10" value="1434.9" spread="651.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>PK Parameter T1/2</title>
        <description>T1/2 = terminal elimination half-life of the compound. Blood samples were taken to assess the P03277 concentration.</description>
        <time_frame>From baseline (30 minutes before injection) to 24 hours post-injection</time_frame>
        <population>In part I, one patient from the &quot;0.025 mmol/kg&quot; group was excluded from the pharmacokinetics analysis (incorrect volume of P03277 injected).
In part II, one patient from the &quot;0.1 mmol/kg&quot; group was excluded from the pharmacokinetics analysis (incorrect route of administration, high probability of extravasation).</population>
        <group_list>
          <group group_id="O1">
            <title>Part I (Phase I) P03277 0.025 mmol/kg</title>
            <description>6 subjects received P03277 in one single administration. P03277 was administered intravenously with a flow rate ranging from 0.5 to 2 mL/s.</description>
          </group>
          <group group_id="O2">
            <title>Part I (Phase I) P03277 0.05 mmol/kg</title>
            <description>6 subjects received P03277 in one single administration. P03277 was administered intravenously with a flow rate ranging from 0.5 to 2 mL/s.</description>
          </group>
          <group group_id="O3">
            <title>Part I (Phase I) P03277 0.075 mmol/kg</title>
            <description>6 subjects received P03277 in one single administration. P03277 was administered intravenously with a flow rate ranging from 0.5 to 2 mL/s.</description>
          </group>
          <group group_id="O4">
            <title>Part I (Phase I) P03277 0.1 mmol/kg</title>
            <description>6 subjects received P03277 in one single administration. P03277 was administered intravenously with a flow rate ranging from 0.5 to 2 mL/s.</description>
          </group>
          <group group_id="O5">
            <title>Part I (Phase I) P03277 0.2 mmol/kg</title>
            <description>6 subjects received P03277 in one single administration. P03277 was administered intravenously with a flow rate ranging from 0.5 to 2 mL/s.</description>
          </group>
          <group group_id="O6">
            <title>Part I (Phase I) P03277 0.3 mmol/kg</title>
            <description>6 subjects received P03277 in one single administration. P03277 was administered intravenously with a flow rate ranging from 0.5 to 2 mL/s.</description>
          </group>
          <group group_id="O7">
            <title>Part II (Phase IIA) 0.05 mmol/kg</title>
            <description>In each dose group, all 3 patients received one single administration of P03277.
P03277 was administered intravenously with a flow rate of 2 mL/s.</description>
          </group>
          <group group_id="O8">
            <title>Part II (Phase IIA) 0.075 mmol/kg</title>
            <description>In each dose group, all 3 patients received one single administration of P03277.
P03277 was administered intravenously with a flow rate of 2 mL/s.</description>
          </group>
          <group group_id="O9">
            <title>Part II (Phase IIA) 0.1 mmol/kg</title>
            <description>In each dose group, all 3 patients received one single administration of P03277.
P03277 was administered intravenously with a flow rate of 2 mL/s.</description>
          </group>
          <group group_id="O10">
            <title>Part II (Phase IIA) 0.2 mmol/kg</title>
            <description>In each dose group, all 3 patients received one single administration of P03277.
P03277 was administered intravenously with a flow rate of 2 mL/s.</description>
          </group>
        </group_list>
        <measure>
          <title>PK Parameter T1/2</title>
          <description>T1/2 = terminal elimination half-life of the compound. Blood samples were taken to assess the P03277 concentration.</description>
          <population>In part I, one patient from the &quot;0.025 mmol/kg&quot; group was excluded from the pharmacokinetics analysis (incorrect volume of P03277 injected).
In part II, one patient from the &quot;0.1 mmol/kg&quot; group was excluded from the pharmacokinetics analysis (incorrect route of administration, high probability of extravasation).</population>
          <units>hours</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="5"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="6"/>
                <count group_id="O5" value="6"/>
                <count group_id="O6" value="6"/>
                <count group_id="O7" value="3"/>
                <count group_id="O8" value="3"/>
                <count group_id="O9" value="2"/>
                <count group_id="O10" value="3"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.65" spread="0.43"/>
                    <measurement group_id="O2" value="1.50" spread="0.22"/>
                    <measurement group_id="O3" value="1.58" spread="0.30"/>
                    <measurement group_id="O4" value="1.73" spread="0.26"/>
                    <measurement group_id="O5" value="1.82" spread="0.35"/>
                    <measurement group_id="O6" value="2.09" spread="0.15"/>
                    <measurement group_id="O7" value="1.90" spread="0.04"/>
                    <measurement group_id="O8" value="2.04" spread="0.06"/>
                    <measurement group_id="O9" value="1.79" spread="0.17"/>
                    <measurement group_id="O10" value="1.94" spread="0.06"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>PK Parameter Cl</title>
        <description>Cl = total clearance. Blood samples were taken to assess the P03277 concentration.</description>
        <time_frame>From baseline (30 minutes before injection) to 24 hours post-injection</time_frame>
        <population>In part I, one patient from the &quot;0.025 mmol/kg&quot; group was excluded from the pharmacokinetics analysis (incorrect volume of P03277 injected).
In part II, one patient from the &quot;0.1 mmol/kg&quot; group was excluded from the pharmacokinetics analysis (incorrect route of administration, high probability of extravasation).</population>
        <group_list>
          <group group_id="O1">
            <title>Part I (Phase I) P03277 0.025 mmol/kg</title>
            <description>6 subjects received P03277 in one single administration. P03277 was administered intravenously with a flow rate ranging from 0.5 to 2 mL/s.</description>
          </group>
          <group group_id="O2">
            <title>Part I (Phase I) P03277 0.05 mmol/kg</title>
            <description>6 subjects received P03277 in one single administration. P03277 was administered intravenously with a flow rate ranging from 0.5 to 2 mL/s.</description>
          </group>
          <group group_id="O3">
            <title>Part I (Phase I) P03277 0.075 mmol/kg</title>
            <description>6 subjects received P03277 in one single administration. P03277 was administered intravenously with a flow rate ranging from 0.5 to 2 mL/s.</description>
          </group>
          <group group_id="O4">
            <title>Part I (Phase I) P03277 0.1 mmol/kg</title>
            <description>6 subjects received P03277 in one single administration. P03277 was administered intravenously with a flow rate ranging from 0.5 to 2 mL/s.</description>
          </group>
          <group group_id="O5">
            <title>Part I (Phase I) P03277 0.2 mmol/kg</title>
            <description>6 subjects received P03277 in one single administration. P03277 was administered intravenously with a flow rate ranging from 0.5 to 2 mL/s.</description>
          </group>
          <group group_id="O6">
            <title>Part I (Phase I) P03277 0.3 mmol/kg</title>
            <description>6 subjects received P03277 in one single administration. P03277 was administered intravenously with a flow rate ranging from 0.5 to 2 mL/s.</description>
          </group>
          <group group_id="O7">
            <title>Part II (Phase IIA) 0.05 mmol/kg</title>
            <description>In each dose group, all 3 patients received one single administration of P03277.
P03277 was administered intravenously with a flow rate of 2 mL/s.</description>
          </group>
          <group group_id="O8">
            <title>Part II (Phase IIA) 0.075 mmol/kg</title>
            <description>In each dose group, all 3 patients received one single administration of P03277.
P03277 was administered intravenously with a flow rate of 2 mL/s.</description>
          </group>
          <group group_id="O9">
            <title>Part II (Phase IIA) 0.1 mmol/kg</title>
            <description>In each dose group, all 3 patients received one single administration of P03277.
P03277 was administered intravenously with a flow rate of 2 mL/s.</description>
          </group>
          <group group_id="O10">
            <title>Part II (Phase IIA) 0.2 mmol/kg</title>
            <description>In each dose group, all 3 patients received one single administration of P03277.
P03277 was administered intravenously with a flow rate of 2 mL/s.</description>
          </group>
        </group_list>
        <measure>
          <title>PK Parameter Cl</title>
          <description>Cl = total clearance. Blood samples were taken to assess the P03277 concentration.</description>
          <population>In part I, one patient from the &quot;0.025 mmol/kg&quot; group was excluded from the pharmacokinetics analysis (incorrect volume of P03277 injected).
In part II, one patient from the &quot;0.1 mmol/kg&quot; group was excluded from the pharmacokinetics analysis (incorrect route of administration, high probability of extravasation).</population>
          <units>mL/min</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="5"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="6"/>
                <count group_id="O5" value="6"/>
                <count group_id="O6" value="6"/>
                <count group_id="O7" value="3"/>
                <count group_id="O8" value="3"/>
                <count group_id="O9" value="2"/>
                <count group_id="O10" value="3"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="91.7" spread="8.5"/>
                    <measurement group_id="O2" value="100.1" spread="9.5"/>
                    <measurement group_id="O3" value="106.4" spread="20.7"/>
                    <measurement group_id="O4" value="96.1" spread="11.8"/>
                    <measurement group_id="O5" value="101.3" spread="10.9"/>
                    <measurement group_id="O6" value="102.2" spread="19.0"/>
                    <measurement group_id="O7" value="105.3" spread="13.5"/>
                    <measurement group_id="O8" value="106.5" spread="15.7"/>
                    <measurement group_id="O9" value="108.6" spread="5"/>
                    <measurement group_id="O10" value="109.9" spread="18.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>PK Parameter Vd</title>
        <description>Vd = volume of distribution. Blood samples were taken to assess the P03277 concentration.</description>
        <time_frame>From baseline (30 minutes before injection) to 24 hours post-injection</time_frame>
        <population>In part I, one patient from the &quot;0.025 mmol/kg&quot; group was excluded from the pharmacokinetics analysis (incorrect volume of P03277 injected).
In part II, one patient from the &quot;0.1 mmol/kg&quot; group was excluded from the pharmacokinetics analysis (incorrect route of administration, high probability of extravasation).</population>
        <group_list>
          <group group_id="O1">
            <title>Part I (Phase I) P03277 0.025 mmol/kg</title>
            <description>6 subjects received P03277 in one single administration. P03277 was administered intravenously with a flow rate ranging from 0.5 to 2 mL/s.</description>
          </group>
          <group group_id="O2">
            <title>Part I (Phase I) P03277 0.05 mmol/kg</title>
            <description>6 subjects received P03277 in one single administration. P03277 was administered intravenously with a flow rate ranging from 0.5 to 2 mL/s.</description>
          </group>
          <group group_id="O3">
            <title>Part I (Phase I) P03277 0.075 mmol/kg</title>
            <description>6 subjects received P03277 in one single administration. P03277 was administered intravenously with a flow rate ranging from 0.5 to 2 mL/s.</description>
          </group>
          <group group_id="O4">
            <title>Part I (Phase I) P03277 0.1 mmol/kg</title>
            <description>6 subjects received P03277 in one single administration. P03277 was administered intravenously with a flow rate ranging from 0.5 to 2 mL/s.</description>
          </group>
          <group group_id="O5">
            <title>Part I (Phase I) P03277 0.2 mmol/kg</title>
            <description>6 subjects received P03277 in one single administration. P03277 was administered intravenously with a flow rate ranging from 0.5 to 2 mL/s.</description>
          </group>
          <group group_id="O6">
            <title>Part I (Phase I) P03277 0.3 mmol/kg</title>
            <description>6 subjects received P03277 in one single administration. P03277 was administered intravenously with a flow rate ranging from 0.5 to 2 mL/s.</description>
          </group>
          <group group_id="O7">
            <title>Part II (Phase IIA) 0.05 mmol/kg</title>
            <description>In each dose group, all 3 patients received one single administration of P03277.
P03277 was administered intravenously with a flow rate of 2 mL/s.</description>
          </group>
          <group group_id="O8">
            <title>Part II (Phase IIA) 0.075 mmol/kg</title>
            <description>In each dose group, all 3 patients received one single administration of P03277.
P03277 was administered intravenously with a flow rate of 2 mL/s.</description>
          </group>
          <group group_id="O9">
            <title>Part II (Phase IIA) 0.1 mmol/kg</title>
            <description>In each dose group, all 3 patients received one single administration of P03277.
P03277 was administered intravenously with a flow rate of 2 mL/s.</description>
          </group>
          <group group_id="O10">
            <title>Part II (Phase IIA) 0.2 mmol/kg</title>
            <description>In each dose group, all 3 patients received one single administration of P03277.
P03277 was administered intravenously with a flow rate of 2 mL/s.</description>
          </group>
        </group_list>
        <measure>
          <title>PK Parameter Vd</title>
          <description>Vd = volume of distribution. Blood samples were taken to assess the P03277 concentration.</description>
          <population>In part I, one patient from the &quot;0.025 mmol/kg&quot; group was excluded from the pharmacokinetics analysis (incorrect volume of P03277 injected).
In part II, one patient from the &quot;0.1 mmol/kg&quot; group was excluded from the pharmacokinetics analysis (incorrect route of administration, high probability of extravasation).</population>
          <units>mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="5"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="6"/>
                <count group_id="O5" value="6"/>
                <count group_id="O6" value="6"/>
                <count group_id="O7" value="3"/>
                <count group_id="O8" value="3"/>
                <count group_id="O9" value="2"/>
                <count group_id="O10" value="3"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13203" spread="4122"/>
                    <measurement group_id="O2" value="12945" spread="1692"/>
                    <measurement group_id="O3" value="14312" spread="2742"/>
                    <measurement group_id="O4" value="14351" spread="2645"/>
                    <measurement group_id="O5" value="15922" spread="3224"/>
                    <measurement group_id="O6" value="18487" spread="3575"/>
                    <measurement group_id="O7" value="17320" spread="1942"/>
                    <measurement group_id="O8" value="18796" spread="2478"/>
                    <measurement group_id="O9" value="16823" spread="804"/>
                    <measurement group_id="O10" value="18355" spread="2522"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>For Part I: adverse events were collected from subjects' enrollment until 7 days after the product (P03277 or placebo) administration. For Part II: adverse events were collected from patients' enrollment until 1 day after P03277 administration.</time_frame>
      <desc>All adverse events occuring pre- and post-injection are reported below.</desc>
      <group_list>
        <group group_id="E1">
          <title>Part I (Phase I) P03277 0.025 mmol/kg</title>
          <description>6 subjects received P03277 in one single administration. P03277 was administered intravenously at 0.025 mmol/kg with a flow rate ranging from 0.5 to 2 mL/s.</description>
        </group>
        <group group_id="E2">
          <title>Part I (Phase I) P03277 0.05 mmol/kg</title>
          <description>6 subjects received P03277 in one single administration. P03277 was administered intravenously at 0.05 mmol/kg with a flow rate ranging from 0.5 to 2 mL/s.</description>
        </group>
        <group group_id="E3">
          <title>Part I (Phase I) P03277 0.075 mmol/kg</title>
          <description>6 subjects received P03277 in one single administration. P03277 was administered intravenously at 0.075 mmol/kg with a flow rate ranging from 0.5 to 2 mL/s.</description>
        </group>
        <group group_id="E4">
          <title>Part I (Phase I) P03277 0.1 mmol/kg</title>
          <description>6 subjects received P03277 in one single administration. P03277 was administered intravenously at 0.1 mmol/kg with a flow rate ranging from 0.5 to 2 mL/s.</description>
        </group>
        <group group_id="E5">
          <title>Part I (Phase I) P03277 0.2 mmol/kg</title>
          <description>6 subjects received P03277 in one single administration. P03277 was administered intravenously at 0.2 mmol/kg with a flow rate ranging from 0.5 to 2 mL/s.</description>
        </group>
        <group group_id="E6">
          <title>Part I (Phase I) P03277 0.3 mmol/kg</title>
          <description>6 subjects received P03277 in one single administration. P03277 was administered intravenously at 0.3 mmol/kg with a flow rate ranging from 0.5 to 2 mL/s.</description>
        </group>
        <group group_id="E7">
          <title>Part I (Phase I) Placebo</title>
          <description>3 healthy subjects per dose group received placebo in one single administration.
Placebo was administered intravenously with a flow rate ranging from 0.5 to 2 mL/s.</description>
        </group>
        <group group_id="E8">
          <title>Part II (Phase IIA) P03277 0.05 mmol/kg</title>
          <description>3 patients received one single administration of P03277. P03277 was administered intravenously at 0.05 mmol/kg with a flow rate of 2 mL/s.</description>
        </group>
        <group group_id="E9">
          <title>Part II (Phase IIA) P03277 0.075 mmol/kg</title>
          <description>3 patients received one single administration of P03277. P03277 was administered intravenously at 0.075 mmol/kg with a flow rate of 2 mL/s.</description>
        </group>
        <group group_id="E10">
          <title>Part II (Phase IIA) P03277 0.1 mmol/kg</title>
          <description>3 patients received one single administration of P03277. P03277 was administered intravenously at 0.1 mmol/kg with a flow rate of 2 mL/s.</description>
        </group>
        <group group_id="E11">
          <title>Part II (Phase IIA) P03277 0.2 mmol/kg</title>
          <description>3 patients received one single administration of P03277. P03277 was administered intravenously at 0.2 mmol/kg with a flow rate of 2 mL/s.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA v16.1</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="3"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="3"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Surgical and medical procedures</title>
            <event_list>
              <event>
                <sub_title>Abortion induced</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E9" events="1" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="3"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_vocab>MedDRA (16.1)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="5" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="3" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="11" subjects_at_risk="18"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E11" subjects_affected="2" subjects_at_risk="3"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Conjunctivitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="3"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="3"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="3"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="3"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Injection site pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" events="2" subjects_affected="2" subjects_at_risk="6"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E7" events="3" subjects_affected="3" subjects_at_risk="18"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="3"/>
              </event>
              <event>
                <sub_title>Catheter site pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" events="3" subjects_affected="3" subjects_at_risk="6"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E11" events="1" subjects_affected="1" subjects_at_risk="3"/>
              </event>
              <event>
                <sub_title>Injection site oedema</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="3"/>
              </event>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="3"/>
              </event>
              <event>
                <sub_title>Catheter site dermatitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="3"/>
              </event>
              <event>
                <sub_title>Catheter site inflammation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="3"/>
              </event>
              <event>
                <sub_title>Injection site coldness</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="3"/>
              </event>
              <event>
                <sub_title>Injection site erythema</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="3"/>
              </event>
              <event>
                <sub_title>Injection site haematoma</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="3"/>
              </event>
              <event>
                <sub_title>Injection site haemorrhage</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="3"/>
              </event>
              <event>
                <sub_title>Injection site inflammation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="3"/>
              </event>
              <event>
                <sub_title>Influenza like illness</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E10" events="1" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="3"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="3"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Contusion</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="3"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Body temperature increased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="3"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Decreased appetite</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="3"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E5" events="2" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E6" events="3" subjects_affected="2" subjects_at_risk="6"/>
                <counts group_id="E7" events="5" subjects_affected="5" subjects_at_risk="18"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E11" events="1" subjects_affected="1" subjects_at_risk="3"/>
              </event>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="3"/>
              </event>
              <event>
                <sub_title>Dizziness postural</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="3"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Pregnancy, puerperium and perinatal conditions</title>
            <event_list>
              <event>
                <sub_title>Pregnancy</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E9" events="1" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="3"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Dysphonia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="3"/>
              </event>
              <event>
                <sub_title>Dyspnoea</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="3"/>
              </event>
              <event>
                <sub_title>Throat irritation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="3"/>
              </event>
              <event>
                <sub_title>Sneezing</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="3"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Dermatitis contact</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="3"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Flushing</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="3"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Jing Hao, MD</name_or_title>
      <organization>Guerbet</organization>
      <phone>+33 (0) 1 45 91 50 00</phone>
      <email>jing.hao@guerbet.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

